Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer | MicrobiomeTrials← Back to trialsNCT04981509
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2022-06-10Est. Completion: 2027-12-31
Enrollment target: 65 participants Locations- UC San Diego Moores Cancer Center, La Jolla, California, United States
- Emory University Hospital Midtown, Atlanta, Georgia, United States
- Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
- Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
- Northwestern University, Chicago, Illinois, United States
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- NCI - Center for Cancer Research, Bethesda, Maryland, United States
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- NYU Langone Hospital - Long Island, Mineola, New York, United States
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
- UT MD Anderson Cancer Center, Houston, Texas, United States
Other microbiome trials you might be interested in
Renal Tumor HistologyCutaneous LeiomyomaKidney Cancer
This study will investigate what causes hereditary leiomyomatosis renal (kidney) cell cancer, or HLRCC, and how the dise…
Bethesda, United States
Kidney CancerUrologic Malignant DisordersRenal Cell CarcinomaFamilial Renal Cancer (FRC)Clear Cell Renal Cancer
We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders.…
Bethesda, United States